OTHER RELEVANT INFORMATION

HOLALUZ-CLIDOM, S.A.

Barcelona, July 1, 2024

In accordance with the provisions of article 227 of the consolidated text of the Law on Market Securities and Investment Services, approved by Royal Legislative Decree 6/2023, of 17 March, and its concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, Holaluz-Clidom, S.A. ("**Holaluz**", the "**Firm**" or the "**Company**") hereby informs you of the following information

OTHER RELEVANT INFORMATION

RESOLUTIONS OF THE ORDINARY GENERAL SHAREHOLDERS' MEETING

At the Ordinary General Shareholders' Meeting of Holaluz, held on 28 June 2024 at 11:00 am, on first call, via teleconference, with the attendance of 17 shareholders present holding 75.29% of the share capital and 70 represented shareholders holding 6.08%, thus having present or represented 87 shareholders holding 81.37% of the Company's share capital, along with the Company's treasury stock representing 0.44% of the share capital, all the proposed resolutions submitted to the General Meeting for approval and decision were approved by the majorities indicated below, the literal tenor of which is as follows:

FIRST ITEM ON THE AGENDA

Annual accounts and corporate management

1.1. Examination and approval, if appropriate, of the Individual Annual Accounts for the financial year ended 31 December 2023 of the Company, duly reviewed by the Company's auditors.

This resolution is approved with the favourable vote of 84 attending shareholders with voting rights, i.e., by a majority of 52.74% of the votes into which the share capital is divided (that is, 64.46% of the capital present and/or represented), and with 3 votes against representing 28.63% of the share capital (that is, 35.00% of the capital present and/or represented), the Individual Annual Accounts for the financial year ended 31 December 2023 of the Company (comprising the Balance Sheet, Profit, and Loss Account, Statement of Changes in Equity, Cash Flow Statement and Notes), all of which have been duly signed by all members of the

Board of Directors, except for Geroa Pentsioak E.P.S.V. de Empleo, and Axon Partners Group Investment, S.G.E.I.C., S.A.U.

1.2. Examination and approval, if appropriate, of the Individual Management Report for the financial year ended 31 December 2023 of the Company, duly reviewed by the Company's auditors.

This resolution is approved with the favourable vote of 84 attending shareholders with voting rights, i.e., by a majority of 52.74% of the votes into which the share capital is divided (that is, 64.46% of the capital present and/or represented), and with 3 votes against representing 28.63% of the share capital (that is, 35.00% of the capital present and/or represented), the Individual Management Report of the Company for the financial year ended 31 December 2023.

1.3. Examination and approval, if appropriate, of the Consolidated Annual Accounts for the financial year ended 31 December 2023 of the Company and its subsidiaries, duly reviewed by the Company's auditors.

This resolution is approved with the favourable vote of 84 attending shareholders with voting rights, i.e., by a majority of 52.74% of the votes into which the share capital is divided (that is, 64.46% of the capital present and/or represented), and with 3 votes against representing 28.63% of the share capital (that is, 35.00% of the capital present and/or represented), the Consolidated Annual Accounts of the Company and its subsidiaries (comprising the Consolidated Statements of Financial Position, Consolidated Income Statements, Consolidated Statements of Comprehensive Income, Consolidated Statements of Changes in Equity, Consolidated Cash Flow Statements and Consolidated Notes) for the financial year ended 31 December 2023 of the Company (comprising the Balance Sheet, Profit and Loss Account, Statement of Changes in Equity, Cash Flow Statement and Notes).

1.4. Examination and approval, if appropriate, of the Consolidated Management Report for the financial year ended 31 December 2023 of the Company and its subsidiaries, duly reviewed by the Company's auditors.

This resolution is approved with the favourable vote of 84 attending shareholders with voting rights, i.e., by a majority of 52.74% of the votes into which the share capital is divided (that is, 64.46% of the capital present and/or represented), and with 3 votes against representing 28.63% of the share capital (that is, 35.00% of the capital present and/or represented), the Consolidated Management Report of the Company and its subsidiaries for the financial year ended 31 December 2023.

The Company's Auditors have issued the mandatory audit reports, which show that both the Annual Accounts and the Management Reports, Individual and Consolidated, comply with the requirements of Article 269 of the Capital Companies Act and other applicable regulations.

1.5. Approval, if appropriate, of the proposed allocation of results for the financial year ended 31 December 2023.

This resolution is approved with the favourable vote of 84 attending shareholders with voting rights, i.e., by a majority of 52.74% of the votes into which the share capital is divided (that is, 64.46% of the capital present and/or represented), and with 3 votes against representing 28.63% of the share capital (that is, 35.00% of the capital present and/or represented), the approval of the distribution of the Company's results for the financial year ended 31 December 2023 with the following details:

Distribution Base

- Profit and loss (losses) -5.449.207.-€

Application

- To previous years' results -5.449.207.-€

1.6. Approval, if appropriate, of the corporate management carried out during the financial year ended 31 December 2023.

This resolution is approved with the favourable vote of 84 attending shareholders with voting rights, i.e., by a majority of 52.74% of the votes into which the share capital is divided (that is, 64.46% of the capital present and/or represented), and with 3 votes against representing 28.63% of the share capital (that is, 35.00% of the capital present and/or represented), the approval of the management of the Company's Board of Directors for the financial year ended 31 December 2023.

SECOND ITEM ON THE AGENDA

Ratification of the appointment by co-option and re-election of the Director Ms. Elena Gómez del Pozuelo as a director, with the qualification of independent director

This resolution is approved with the favourable vote of 82 attending shareholders with voting rights, i.e., by a majority of 49.42% of the votes into which the share capital is divided (that is, 60.40% of the capital present and/or represented), and with 5 votes against representing 31.95% of the share capital (that is, 39.06% of the capital present and/or represented), the ratification of the appointment by co-option of Ms. Elena Gómez de Pozuelo made by the Board of Directors on 3 October 2023, and her re-election as a director of the Company, with the category of independent director, for the statutory term of six years from the date of this General Shareholders' Meeting.

THIRD ITEM ON THE AGENDA

Ratification of the appointment by co-option and re-election of the Director Mr. Eduardo Soler Vila as a director, with the qualification of independent director

This resolution is approved with the favourable vote of 80 attending shareholders with voting rights, i.e., by a majority of 47.34% of the votes into which the share capital is divided (that is, 57.86% of the capital present and/or represented), and with 7 votes against representing 34.03% of the share capital (that is, 41.60% of the capital present and/or represented), the ratification of the appointment by co-option of Mr. Eduardo Soler Vila, made by the Board of Directors on 18 March 2024, and his re-election as a director of the Company, with the category of independent director, for the statutory term of six years from the date of this General Shareholders' Meeting.

FOURTH ITEM ON THE AGENDA

Authorisation to the Board of Directors to proceed with the derivative acquisition of treasury shares, either directly or through its controlled companies, up to a maximum of 10% of the share capital, and their subsequent disposal

This resolution is approved with the favourable vote of 84 attending shareholders with voting rights, i.e., by a majority of 52.74% of the votes into which the share capital is divided (that is, 64.46% of the capital present and/or represented), and with 3 votes against representing 28.63% of the share capital (that is, 35.00% of the capital present and/or represented), the authorisation to the Company's Board of Directors to proceed with the derivative acquisition of treasury shares, both directly by the Company itself and indirectly through its subsidiary companies, under the following terms:

(i) The acquisition may be made by way of purchase, exchange, donation, adjudication or dation in payment and, in general, by any other method of acquisition for valuable consideration of outstanding and fully paid-up shares permitted by Law. The acquisition of shares may be carried out by any of the aforementioned methods, on one or more occasions, provided that the shares acquired, added to those already held by the Company, do not exceed 10% of the share capital.

(ii) The price or consideration shall range between a minimum equivalent to their nominal value and a maximum equivalent to 110% of the trading price of the Company's shares on the BME Growth segment of BME MTF Equity at the time of acquisition.

(iii) The period of validity of the authorisation shall be five years from the date of this resolution.

It is expressly stated that the shares acquired as a result of this authorisation may be used for disposal or amortisation, for the achievement of potential corporate or business operations, or for delivery directly to the employees or directors of the Company, or as a consequence of the

exercise of option rights of which they are holders, in accordance with the provisions of the third paragraph of section 1.a) of Article 146 of the Capital Companies Act.

FIFTH ITEM ON THE AGENDA

Delegation of powers to the Board of Directors, with express power of substitution, for the formalisation, interpretation, rectification and/or execution of the resolutions adopted by the General Meeting

This resolution is approved with the favourable vote of 86 attending shareholders with voting rights, i.e., by a majority of 64.57% of the votes into which the share capital is divided (that is, 78.91% of the capital present and/or represented), and with 1 vote against representing 16.80% of the share capital (that is, 20.55% of the capital present and/or represented), the delegation and, insofar as may be necessary, expressly empowering the Board of Directors, which may delegate, jointly and severally to the Chairman of the Board of Directors, to the non-director Secretary and Vice-Secretary, and to the Directors, so that any of them, jointly and severally, may formalise, interpret, develop, apply, execute, rectify and notarise the resolutions adopted at this General Meeting and, in particular, proceed to file with the Commercial Registry, for deposit, the certification of the resolutions approving the annual accounts and the allocation of results, attaching the documents legally required, as well as to execute as many public and/or private documents as may be necessary until the corresponding registration in the Commercial Registry of the resolutions adopted is obtained, including the request for partial registration, with powers, even, for rectification or correction in view of the assessment that may be made by the Registrar.

PROPOSED RESOLUTION NOT INCLUDED IN THE AGENDA

Corporate liability action against the directors Geroa Pentsioak E.P.S.V. de Empleo, represented by Mr Jordan Sáenz Leal and Axon Partners Group Investment, S.G.E.I.C., S.A.U., represented by Mr Alfonso Juan de León Castillejo

In accordance with the proposed resolution outside the agenda made in the interventions of two shareholders of the Company for the Company to file a corporate liability action against the directors Geroa Pentsioak E.P.S.V. de Empleo, represented by Mr Jordan Sáenz Leal and Axon Partners Group Investment, S.G.E.I.C., S.A.U., represented by Mr Alfonso Juan de León Castillejo, this resolution is approved with the favourable vote of 76 attending shareholders with voting rights, i.e., by a majority of 47.00% of the votes into which the share capital is divided (that is, 57.45% of the capital present and/or represented), and with 11 votes against representing 34.37% of the share capital (that is, 42.01% of the capital present and/or represented), with the consequence that Geroa Pentsioak E.P.S.V. de Empleo, represented by Mr Jordan Sáenz Leal and Axon Partners Group Investment, S.G.E.I.C., S.A.U., represented by Mr Alfonso Juan de León Castillejo, are automatically removed from their positions, which will be registered in the Commercial Registry as soon as possible. The Board of Directors has

taken note of the resolution adopted by the General Meeting to file the corporate liability action against said directors.

In compliance with the provisions of Circular 3/2020 of BME MTF Equity, it is expressly stated that the information communicated hereby has been prepared under the exclusive responsibility of the Company and its directors.

In Barcelona, on 1 July 2024.

_____

Ms. Carlota Pi Amorós
Executive Chairwoman
HOLALUZ-CLIDOM, S.A.